Australian scientists report success so far in a clinical trial of a gene-therapy for treating wet age-related macular degeneration, triggered by excessive vascular endothelial growth factor in the retina. A Phase I trial at the Lions Eye Institute in Perth conducted with a license from U.S.-based Avalanche Biotechnologies reported "excellent" results without serious adverse side effects. The treatment involves injecting a modified virus with a particular gene to stimulate a protein to block excessive production of VGEF. (Click here for more
)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?